title: NK cell immunotherapy for high-risk neuroblastoma relapse after haploidentical HSCT.
abstract: Little is known on strategies to prevent or to treat relapses occurring after haploidentical stem cell transplantation (haplo-HSCT) performed for the high-risk neuroblastoma (NB). We describe a 6-year-old male with refractory NB who relapsed 22 months after haplo-HSCT. A complete remission was obtained with a combination of immuno-chemotherapy based on donor NK cells transplants, IL2 infusions and temozolomide/topotecan. This case is an incentive to explore both the immediate therapeutic effect of haplo-graft provided via haplo-NK cells and the immunogenic platform that haplo-HSCT offers for future treatment. Our post-relapse strategy shows that chemo- and bio-treatment should be viewed as complementary therapeutic options.
authors.affiliation: CHU Clermont Ferrand, Centre Régional de Cancérologie et Thérapie Cellulaire Pédiatrique, CHU Estaing, Clermont Ferrand, France. jkanold@chu-clermontferrand.fr
authors.forename: Justyna
authors.initials: J
authors.lastname: Kanold
authors.forename: Catherine
authors.initials: C
authors.lastname: Paillard
authors.forename: Andrei
authors.initials: A
authors.lastname: Tchirkov
authors.forename: Peter
authors.initials: P
authors.lastname: Lang
authors.forename: Antony
authors.initials: A
authors.lastname: Kelly
authors.forename: Pascale
authors.initials: P
authors.lastname: Halle
authors.forename: Florentina
authors.initials: F
authors.lastname: Isfan
authors.forename: Etienne
authors.initials: E
authors.lastname: Merlin
authors.forename: Aurelien
authors.initials: A
authors.lastname: Marabelle
authors.forename: Emmanuelle
authors.initials: E
authors.lastname: Rochette
authors.forename: François
authors.initials: F
authors.lastname: Deméocq
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000473:pathology / Q000628:therapy*; D018906:Antineoplastic Agents, Alkylating / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis; D019046:Bone Marrow Neoplasms / Q000556:secondary; D001859:Bone Neoplasms / Q000556:secondary; D002648:Child; D003131:Combined Modality Therapy; D003606:Dacarbazine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000089622:Doublecortin Domain Proteins; D006239:Haplotypes; D018380:Hematopoietic Stem Cell Transplantation; D018398:Homeodomain Proteins / Q000032:analysis; D006801:Humans; D007167:Immunotherapy; D007376:Interleukin-2 / Q000627:therapeutic use; D007694:Killer Cells, Natural / Q000637:transplantation*; D008297:Male; D008869:Microtubule-Associated Proteins; D018365:Neoplasm, Residual; D009447:Neuroblastoma / Q000473:pathology / Q000556:secondary / Q000628:therapy*; D009479:Neuropeptides; D012074:Remission Induction; D000077204:Temozolomide; D019772:Topotecan / Q000627:therapeutic use; D014157:Transcription Factors / Q000032:analysis; D014184:Transplantation, Homologous; D014446:Tyrosine 3-Monooxygenase / Q000032:analysis
chemical_list: D018906:Antineoplastic Agents, Alkylating; D014408:Biomarkers, Tumor; D000089622:Doublecortin Domain Proteins; D018398:Homeodomain Proteins; D007376:Interleukin-2; D008869:Microtubule-Associated Proteins; C109220:NBPhox protein; D009479:Neuropeptides; D014157:Transcription Factors; D003606:Dacarbazine; D019772:Topotecan; D014446:Tyrosine 3-Monooxygenase; D000077204:Temozolomide